Apex Medical Corp. (4106.TW)
TWD 24.5
(1.24%)
TWD 24.5
(1.24%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 364.55 Million TWD | -24.99% |
| 2022 | 486 Million TWD | -11.0% |
| 2021 | 546.04 Million TWD | 26.56% |
| 2020 | 431.43 Million TWD | -33.94% |
| 2019 | 653.13 Million TWD | -6.28% |
| 2018 | 696.88 Million TWD | 21.9% |
| 2017 | 571.69 Million TWD | -6.65% |
| 2016 | 612.42 Million TWD | 22.23% |
| 2015 | 501.06 Million TWD | 165.17% |
| 2014 | 188.96 Million TWD | -31.22% |
| 2013 | 274.72 Million TWD | 7.8% |
| 2012 | 254.84 Million TWD | 50.23% |
| 2011 | 169.63 Million TWD | 157.95% |
| 2010 | 65.76 Million TWD | -46.92% |
| 2009 | 123.89 Million TWD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 382.12 Million TWD | 4.82% |
| 2024 Q2 | 309.41 Million TWD | -19.03% |
| 2023 Q3 | 390.34 Million TWD | -4.14% |
| 2023 Q1 | 424.36 Million TWD | -12.68% |
| 2023 FY | 364.55 Million TWD | -24.99% |
| 2023 Q4 | 364.55 Million TWD | -6.61% |
| 2023 Q2 | 407.19 Million TWD | -4.04% |
| 2022 Q3 | 576.6 Million TWD | -4.51% |
| 2022 FY | 486 Million TWD | -11.0% |
| 2022 Q4 | 486 Million TWD | -15.71% |
| 2022 Q1 | 574.66 Million TWD | 5.24% |
| 2022 Q2 | 603.84 Million TWD | 5.08% |
| 2021 FY | 546.04 Million TWD | 26.56% |
| 2021 Q3 | 502.63 Million TWD | -1.79% |
| 2021 Q4 | 546.04 Million TWD | 8.64% |
| 2021 Q1 | 428.2 Million TWD | -0.75% |
| 2021 Q2 | 511.8 Million TWD | 19.52% |
| 2020 Q2 | 684.27 Million TWD | 23.54% |
| 2020 FY | 431.43 Million TWD | -33.94% |
| 2020 Q3 | 626.24 Million TWD | -8.48% |
| 2020 Q4 | 431.43 Million TWD | -31.11% |
| 2020 Q1 | 553.9 Million TWD | -15.19% |
| 2019 Q1 | 769.43 Million TWD | 10.41% |
| 2019 Q3 | 805.22 Million TWD | 0.86% |
| 2019 Q4 | 653.13 Million TWD | -18.89% |
| 2019 FY | 653.13 Million TWD | -6.28% |
| 2019 Q2 | 798.35 Million TWD | 3.76% |
| 2018 Q2 | 568.18 Million TWD | 2.4% |
| 2018 Q3 | 594.3 Million TWD | 4.6% |
| 2018 Q4 | 696.88 Million TWD | 17.26% |
| 2018 Q1 | 554.86 Million TWD | -2.94% |
| 2018 FY | 696.88 Million TWD | 21.9% |
| 2017 Q1 | 611.78 Million TWD | -0.1% |
| 2017 FY | 571.69 Million TWD | -6.65% |
| 2017 Q4 | 571.69 Million TWD | -9.34% |
| 2017 Q3 | 630.63 Million TWD | -4.39% |
| 2017 Q2 | 659.57 Million TWD | 7.81% |
| 2016 Q2 | 574.37 Million TWD | -4.42% |
| 2016 Q3 | 544.5 Million TWD | -5.2% |
| 2016 Q4 | 612.42 Million TWD | 12.48% |
| 2016 Q1 | 600.95 Million TWD | 19.94% |
| 2016 FY | 612.42 Million TWD | 22.23% |
| 2015 FY | 501.06 Million TWD | 165.17% |
| 2015 Q4 | 501.06 Million TWD | -2.17% |
| 2015 Q3 | 512.18 Million TWD | 140.99% |
| 2015 Q1 | 156.29 Million TWD | -17.28% |
| 2015 Q2 | 212.53 Million TWD | 35.98% |
| 2014 Q2 | 246.59 Million TWD | -10.75% |
| 2014 FY | 188.96 Million TWD | -31.22% |
| 2014 Q1 | 276.29 Million TWD | 0.57% |
| 2014 Q3 | 236.64 Million TWD | -4.03% |
| 2014 Q4 | 188.96 Million TWD | -20.15% |
| 2013 Q1 | 187.55 Million TWD | -26.4% |
| 2013 FY | 274.72 Million TWD | 7.8% |
| 2013 Q4 | 274.72 Million TWD | 4.52% |
| 2013 Q3 | 262.83 Million TWD | 62.59% |
| 2013 Q2 | 161.65 Million TWD | -13.81% |
| 2012 Q1 | 110.09 Million TWD | -35.1% |
| 2012 FY | 254.84 Million TWD | 50.23% |
| 2012 Q4 | 254.84 Million TWD | -7.85% |
| 2012 Q3 | 276.55 Million TWD | 428.04% |
| 2012 Q2 | 52.37 Million TWD | -52.43% |
| 2011 Q2 | 44 Million TWD | -33.09% |
| 2011 FY | 169.63 Million TWD | 157.95% |
| 2011 Q1 | 65.76 Million TWD | -0.0% |
| 2011 Q3 | 33.6 Million TWD | -23.62% |
| 2011 Q4 | 169.63 Million TWD | 404.75% |
| 2010 FY | 65.76 Million TWD | -46.92% |
| 2010 Q4 | 65.76 Million TWD | 0.0% |
| 2009 FY | 123.89 Million TWD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Excelsior Medical Co., Ltd. | 1.44 Billion TWD | 74.745% |
| OK Biotech Co., Ltd. | 332.97 Million TWD | -9.483% |
| Applied BioCode Corporation | 34.43 Million TWD | -958.79% |